Teva HD candidate pridopidine heading for Phase III

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hopes to begin a Phase III program next year of pridopidine to treat Huntington's disease after seeing possible evidence of a disease-modifying effect in the exploratory Phase II PRIDE-HD study.

The company said some doses of pridopidine led to a "statistically significant impact" on disease progression as measured by total functional capacity (TFC) at 52 weeks in PRIDE-HD's total patient population and in patients with early stage disease. ...